| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/18/2004 | US20040053259 Comprises methylated antisense oligonucleotide sequence for regulation of urokinase type plasminogen activator and treatment of cancer |
| 03/18/2004 | US20040052881 Compositions and methods for cancer prevention and treatment derived from Inula britannica |
| 03/18/2004 | US20040052879 Solvent extraction with methanol; isomerization; antitumor agents |
| 03/18/2004 | US20040052873 Bioavailability / bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof |
| 03/18/2004 | US20040052870 Cyclooxygenase (COX-2) inhibitors; for treatment/prevention of inflammation; nutraceuticals; for treatment of nervous system disorders |
| 03/18/2004 | US20040052869 Orally ingestible preparation of mistletoe lectins and method |
| 03/18/2004 | US20040052864 Comprises decitabine as methylation inhibitor; kits; tumor suppressor genes/proteins; interleukins; vaccines |
| 03/18/2004 | US20040052812 Immunogenic complex containing a multi-component viral particle covalently linked to a javelin molecule, wherein the javelin molecule is a peptide which selectively binds to a heat shock protein |
| 03/18/2004 | US20040052796 Anticancer agents; antitumor agents; controlling gene expression; quantitative analysis |
| 03/18/2004 | US20040052785 Synergistic mixtures; antitumor agents |
| 03/18/2004 | US20040052773 Production of multi-chain protein from muscle |
| 03/18/2004 | US20040052769 Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease |
| 03/18/2004 | US20040052761 Sustaine release; drug delivery; injections |
| 03/18/2004 | US20040052729 Immobilization carbohydrates; calibration; diagnosis; antiinflammatory agents, bactericides |
| 03/18/2004 | DE10239832A1 New sarcolysine derivatives, e.g. amide or peptide compounds, useful as anticancer agents with reduced toxicity to healthy cells |
| 03/18/2004 | CA2498297A1 Recombinatant mutants of rhabdovirus and methods of use thereof |
| 03/18/2004 | CA2497901A1 Furan or thiophene derivative and medicinal use thereof |
| 03/18/2004 | CA2497873A1 Novel diagnostic and therapeutic methods and reagents therefor |
| 03/18/2004 | CA2497836A1 A method of modulating endothelial cell activity |
| 03/18/2004 | CA2497833A1 A method of modulating cellular activity and molecules for use therein |
| 03/18/2004 | CA2497792A1 Cyclodextrin-based polymers for therapeutics delivery |
| 03/18/2004 | CA2497644A1 Whole bacterial cells as immune modulator |
| 03/18/2004 | CA2497552A1 Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| 03/18/2004 | CA2497246A1 Neoadjuvant treatment of breast cancer |
| 03/18/2004 | CA2497180A1 Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist |
| 03/18/2004 | CA2496566A1 Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer |
| 03/18/2004 | CA2495939A1 Cathepsin cysteine protease inhibitors |
| 03/18/2004 | CA2495442A1 Backbone-substituted bifunctional dota ligands, complexes and compositions thereof, and methods of using same |
| 03/18/2004 | CA2495284A1 Diarylurea derivatives and their use as chloride channel blockers |
| 03/18/2004 | CA2493974A1 Pharmaceutical dosage form comprising a sulfite compound |
| 03/17/2004 | EP1398377A1 Growth differentation Factor-7 |
| 03/17/2004 | EP1398037A2 Pharmaceutical formulations comprising a water-insoluble complex for sustained drug delivery |
| 03/17/2004 | EP1398036A1 Ganoderma lucidum spores for treatment of autoimmune diseases |
| 03/17/2004 | EP1398033A2 Use of benzodiazepines for treating autoimmune diseases, inflammations, neoplasies, viral infections and atherosclerosis |
| 03/17/2004 | EP1398031A1 Use of 6-amino-quinoline-5,8-quinones and nucleic acids associated with senescence for the treatment of tumors |
| 03/17/2004 | EP1398028A2 Taxanes having alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing same |
| 03/17/2004 | EP1398025A1 Fine inorganic particles having drug included therein, method for preparation thereof and pharmaceutical preparation comprising fine inorganic particles having drug included therein |
| 03/17/2004 | EP1397507A1 Methods and compositions for treating cardiovascular disease using 10218 |
| 03/17/2004 | EP1397500A2 Improved transfection of eukaryotic cells with linear polynucleotides by electroporation |
| 03/17/2004 | EP1397495A2 22437, a human sulfatase and uses therefor |
| 03/17/2004 | EP1397489A2 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof |
| 03/17/2004 | EP1397387A1 Antibodies specific for cd44v6 |
| 03/17/2004 | EP1397386A2 Chimeric proteins for cell targeting and apoptosis induction and methods of using the same |
| 03/17/2004 | EP1397382A2 Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions |
| 03/17/2004 | EP1397374A2 Siglec inhibitors |
| 03/17/2004 | EP1397369A1 New use or cyclolignans and new cyclolignans |
| 03/17/2004 | EP1397368A1 New use of specific cyclolignans |
| 03/17/2004 | EP1397365A1 Novel heteroaryl-diazabicyclo-alkanes as cns-modulators |
| 03/17/2004 | EP1397364A1 Novel pyrrole derivatives as pharmaceutical agents |
| 03/17/2004 | EP1397363A1 5-ethyl-imidazotriazinones |
| 03/17/2004 | EP1397360A1 Azaindoles |
| 03/17/2004 | EP1397359A1 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
| 03/17/2004 | EP1397356A1 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1) |
| 03/17/2004 | EP1397355A1 Pyridyl cyanoguanidine compounds |
| 03/17/2004 | EP1397354A1 Imidazole-2-carboxamide derivatives as raf kinase inhibitors |
| 03/17/2004 | EP1397350A1 Isoquinolinone derivatives as parp inhibitors |
| 03/17/2004 | EP1397340A2 Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors |
| 03/17/2004 | EP1397172A1 Safety shield system for prefilled syringes |
| 03/17/2004 | EP1397170A1 Safety shield system for prefilled syringes |
| 03/17/2004 | EP1397162A2 Water-soluble antibiotic comprising an amino sugar, in the form of a polysaccharide conjugate |
| 03/17/2004 | EP1397153A2 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 03/17/2004 | EP1397151A2 Wnv core protein/capsid interacting protein and uses of the same |
| 03/17/2004 | EP1397150A2 Somatostatin agonists |
| 03/17/2004 | EP1397142A2 Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| 03/17/2004 | EP1397137A1 Hydantion derivatives as inhibitors of matrix metalloproteinases |
| 03/17/2004 | EP1397105A1 Methods for inhibiting angiogenesis |
| 03/17/2004 | EP1292597B1 Carbamate and thiocarbamate podophyllotoxin derivatives, preparation method and pharmaceutical compositions containing them |
| 03/17/2004 | EP1242406B1 Novel compounds |
| 03/17/2004 | EP1242364B1 Adamantane derivatives |
| 03/17/2004 | EP1147102B1 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
| 03/17/2004 | EP1140936B1 Tricyclic inhibitors of poly(adp-ribose) polymerases |
| 03/17/2004 | EP1100792B1 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases |
| 03/17/2004 | EP1079851A4 Use of anti-prolactin agents to treat proliferative conditions |
| 03/17/2004 | EP1071684B1 IMIDAZO 1,2-a]PYRIDINES AS PERIPHERAL BENZODIAZEPINE RECEPTOR BINDING AGENTS |
| 03/17/2004 | EP1030686B1 Lyophilizate of lipid complex of water insoluble porphyrins |
| 03/17/2004 | EP0951471B1 Cycloalkyl inhibitors of protein farnesyltransferase |
| 03/17/2004 | EP0925301B1 Highly lipophilic camptothecin derivatives |
| 03/17/2004 | EP0915974B1 Modified tie-2-receptor ligands |
| 03/17/2004 | EP0891362B1 Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase |
| 03/17/2004 | CN1483079A Immunoregulation polynucleotide and using method thereof |
| 03/17/2004 | CN1483035A Sulfamidothienopyrimidines |
| 03/17/2004 | CN1483033A Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors |
| 03/17/2004 | CN1483032A Process for making substituted 8-arylquinolinium benzenesulfonate |
| 03/17/2004 | CN1483028A Quinolinone derivatives as tyrosine kinase inhibitors |
| 03/17/2004 | CN1483026A Benzoylpyridazine |
| 03/17/2004 | CN1483024A Vla-4 inhibitors |
| 03/17/2004 | CN1483023A 3-arylindole derivatives and their use as cb2 receptor agonists |
| 03/17/2004 | CN1483019A Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines |
| 03/17/2004 | CN1482918A Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders |
| 03/17/2004 | CN1482917A New therapeutic uses of smr1 peptides |
| 03/17/2004 | CN1482916A Vaccine composite containing invert growth factor a |
| 03/17/2004 | CN1482915A Natural constituents for suppressing production of blood vessel, its preparation method and use |
| 03/17/2004 | CN1482906A New clinical treatment |
| 03/17/2004 | CN1482238A Preparation method for tumour cell comprising interleukin-23 gene and its use |
| 03/17/2004 | CN1482129A Process for promoting generation of 10-hydroxycamptothecin in the bud of camptotheca seed |
| 03/17/2004 | CN1482128A 7-esterified and 7,20-double esterified camptothecine derivant and method for preparing the same and pharmaceutical combination and uses thereof |
| 03/17/2004 | CN1481901A Hla matching donor-originating activated lymphocytes |
| 03/17/2004 | CN1481862A Chinese traditional medicine composition curing viscera inflammation, toxin and endocrine disorder |
| 03/17/2004 | CN1481836A Traditional Chinese medicine for malignancy |
| 03/17/2004 | CN1481827A Extracts of cacao bean and cacao bean husk with inhibitory effects on carcinogenesis |